04.13.21

Bausch + Lomb Announces Topline Results From The First Phase 3 Trial Of NOV03 In Dry Eye Disease Associated With MGD

Source: Bausch + Lomb

04.07.21

FDA Approves Bausch + Lomb ClearVisc Dispersive Ophthalmic Viscosurgical Device (OVD)

Source: Bausch + Lomb

03.12.21

Bausch Health Announces CFO Succession Plan

Source: Bausch Health

02.23.21

Bausch + Lomb Launches Alaway Preservative Free Antihistamine Eye Drops

Source: Bausch + Lomb

02.15.21

Icahn to Push for Changes at Bausch Health After Disclosing Stake

Source: FirstWord

02.01.21

Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Wet AMD

Source: Bausch + Lomb

01.19.21

Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (Perfluorohexyloctane)

Source: Bausch + Lomb

01.06.21

Nicox’s Licensee Bausch + Lomb Launches Vyzulta in Mexico

Source: Nicox

12.22.20

Nicox’s Licensee Bausch + Lomb Secures Approval of Vyzulta in Colombia

Source: Nicox

11.24.20

Bausch Health Initiates Second Phase 3 Study for Investigational Treatment for Dry Eye Disease Associated With MGD

Source: Bausch Health Companies Inc.

View more stories